Afecções residuais mínimas (DRM) baseadas no ADNc — monitorização pós-tratamento
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BIO-CTDNA-MRD-POST-TREATMENT |
|---|---|
| Tipo | Biomarcador |
| Alegais | Monitoramento do MRD ctDNActDNA MRD pós-tratamentodoença molecular residual pós-tratamentoCtDNA série MRDцтДНК-MRD — моніторинг після лікування |
| Estado | reviewed 2026-05-18 | pending_clinical_signoff |
| Doenças | DIS-BREAST DIS-CRC |
| Fontes | SRC-CIVIC SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 |
Fatos de biomarcadores
| Tipo de biomarcador | composite_score |
|---|---|
| Medição | MétodoBiópsia líquida em série (Plasma cfDNA): informada do tumor (Signatera, RaDaR, NeXT Personal — painel multi-locus específico do paciente do tumor primário WES) OU ensaio do ctDNA do painel fixo do tumor agnóstico Unidadescategorical (MRD-positive | MRD-negative) + quantitative (mean tumor molecules per mL plasma, MTM/mL, or VAF) |
| Biomarcadores relacionados | BIO-CTDNA-MRD |
Notas
Companion entry to BIO-CTDNA-MRD focused on POST-TREATMENT serial surveillance (vs. single landmark timepoint). Distinct from MCED (BIO-CFDNA-METHYLATION-MCED) in that ctDNA-MRD assumes a known prior cancer diagnosis with post-curative-intent surgery / chemoradiation. Strongest evidence in CRC (GALAXY / CIRCULATE-Japan, Kotani Nat Med 2023): MRD-positive post-op patients ~22% 18-mo DFS vs ~93% MRD- negative; MRD-positive benefit from adjuvant chemotherapy. Emerging evidence in muscle-invasive bladder cancer (IMvigor010 ctDNA subgroup), early breast cancer (c-TRAK-TN), NSCLC (post-IMpower010 retrospectives), pancreatic, gastric. Trial frameworks for MRD-driven escalation/de-escalation: CIRCULATE-Japan ALTAIR/VEGA, NRG-GI008 (CIRCULATE-US), DYNAMIC-IV. ESMO 2024 endorses ctDNA-MRD as a prognostic biomarker for CRC stage II adjuvant decision-making (May inform adjuvant chemo discussion when MRD+ at 4-8 weeks post-op). NOT recommended for asymptomatic-population screening — entry is surveillance of KNOWN prior cancer survivors. `applicable_in_asymptomatic: false` — patient has documented cancer history, not asymptomatic in the prevention sense. Caveats: assay LOD ~0.01% VAF, micrometa...
Usado por
Relevância terapêutica
BMA-CTDNA-MRD-POST-TREATMENT-BREAST- Ensaios de ADNc personalizados do tumor detectam MRD antes do recur...BMA-CTDNA-MRD-POST-TREATMENT-CRC- Positividade pós-ressecção do ADN-MRD na fase II/III do câncer colorretal identifica pacientes...